Validation of Intermediate End Points in Cancer Research
The DOI matches its Crossref record.
Abstract
Investigations using intermediate end points as cancer surrogates are quicker, smaller, and less expensive than studies that use malignancy as the end point. We present a strategy for determining whether a given biomarker is a valid intermediate end point between an exposure and incidence of cancer. Candidate intermediate end points may be selected from case series, ecologic studies, and animal experiments. Prospective cohort and sometimes case-control studies may be used to quantify the intermediate end point-cancer association. The most appropriate measure of this association is the attributable proportion. The intermediate end point is a valid cancer surrogate if the attributable proportion is close to 1.0, but not if it is close to 0. Usually, the attributable proportion is close to neither 1.0 nor 0; in this case, valid surrogacy requires that the intermediate end point mediate an established exposure-cancer relation. This would in turn imply that the exposure effect would vanish if adjusted for the intermediate end point. We discuss the relative advantages of intervention and observational studies for the validation of intermediate end points. This validation strategy also may be applied to intermediate end points for adverse reproductive outcomes and chronic diseases other than cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Schiffman, M. H., Bauer, H. M., Hoover, R. N., Glass, A. G., Cadell, D. M., Rush, B. B., Scott, D. R., Sherman, M. E., Kurman, R. J., Wacholder, S., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.12.958 · Cited by 1,210
Self-citationStatistical validation of intermediate endpoints for chronic diseases
Freedman, L. S., Graubard, B. I., & Schatzkin, A. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110204 · Cited by 651
Self-citationFenech, M., Holland, N., Chang, W. P., Zeiger, E., & Bonassi, S. (1999) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s1383-5742(99)00053-8 · Cited by 605
Population-Based Study of Human Papillomavirus Infection and Cervical Neoplasia in Rural Costa Rica
Herrero, R., Hildesheim, A., Bratti, C., Sherman, M. E., Hutchinson, M., Morales, J., Balmaceda, I., Greenberg, M. D., Alfaro, M., Burk, R. D., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.6.464 · Cited by 586
Self-citationThurston, G. D., Kipen, H., Annesi-Maesano, I., Balmes, J., Brook, R. D., Cromar, K., De Matteis, S., Forastiere, F., Forsberg, B., Frampton, M. W., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00419-2016 · Cited by 537
Metadata
- Authors
- Schatzkin, A., Freedman, L. S., Schiffman, M. H., & Dawsey, S. M.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 1990-11-21
- Volume
- 82
- Issue
- 22
- Pages
- 1746-1752
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2056459926
- Cited by
- 156
- References
- 0
- FWCI
- 11.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Validation of Intermediate End Points in Cancer Research. https://app.cochat.ai/papers/10.1093/jnci/82.22.1746
- The paper
- Schatzkin, A., Freedman, L. S., Schiffman, M. H., & Dawsey, S. M. (1990). Validation of Intermediate End Points in Cancer Research. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/82.22.1746
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.